肿瘤医生

1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V1.2024
2. FRANCIS P A, PAGANI O, FLEMING G F, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer ［J］. N Engl J Med, 2018, 379(2): 122-137.
3. NOH W C, LEE J W, NAM S J, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study ［J］. J Clin Oncol, 2018, 36(15_suppl): 502.
4. TAN S H, WOLFF A C. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer［J］. Clin Breast Cancer, 2007, 7(6): 455-464.
5. Shiba E, Yamashita H, Kurebayashi J, et al. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every‑3‑months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine‑responsive breast cancer[J]. Breast Cancer, 2016, 23(3):499‑509. DOI: 10.1007/s12282‑015‑0593‑z.
6. Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre‑and perimenopausal breast cancer patients[J]. Cancer Chemother Pharmacol, 1999, 43(6): 461‑466. DOI: 10.1007/s002800050924.
7. Masuda N, Iwata H, Rai Y, et al. Monthly versus 3‑monthly goserelin acetate treatment in pre‑menopausal patients with estrogen receptor‑positive early breast cancer[J]. Breast Cancer Res Treat, 2011, 126(2): 443‑451. DOI: 10.1007/s10549‑010‑1332‑y.
8. Kim HA, Lee JW, Nam SJ, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: A randomized phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(5): 434‑443. DOI: 10.1200/JCO.19.00126.
9. Aydiner A, Kilic L, Yildiz I, et al. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients[J]. Med Oncol, 2013, 30(1):354. DOI: 10.1007/s12032-012-0354-1.
10. Lee YJ, Wu ZY, Kim HJ, et al. Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen[J]. J Breast Cancer, 2020, 23(5):553-559. DOI: 10.4048/jbc.2020.23.e57.
11. Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients[J]. Cancer Chemother Pharmacol, 1999, 43(6):461-466. DOI: 10.1007/s002800050924.
12. DE CIANTIS M，FAURE C，HEUDELP E，et a1．Ovarian suppression failure during GnRH agonist treatment：a report of three breast cancer patients[J]．J Gynecol Obstet Hum Reprod，2018，47(6)：261—264．
13. BELLET M，GRAYK P，FRANCISP A，et a1．Twelve—month estrogen levels in premenopansal women with hormone receptor。positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial(SOFT)：the SOFT—EST sub-study[J]．J Clin Oncol， 2016，34(14)：1584—1593．
14. Schmid P, Untch M, Kossé V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study[J]. J Clin Oncol, 2007, 25(18):2509-2515. DOI: 10.1200/JCO.2006.08.8534.
15. Kurebayashi J, Toyama T, Sumino S, et al. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study[J]. Breast Cancer, 2017, 24(1):161-170. DOI: 10.1007/s12282-016-0691-6.
16. 陈祎霏, 严颖, 姜晗昉, 等. 促性腺激素释放激素激动剂对绝经前激素受体阳性乳腺癌患者去势效果分析——真实世界研究[J]. 军事医学, 2021, 45(05):373-379.
17. 江泽飞,王晓迪.乳腺癌内分泌治疗十个热点问题的思考[J]. 中华外科杂志, 2015, 2(12): 895-900.
18. 宋三泰, 陈建魁, 单彬. 规范乳腺癌性激素化验报告理顺应用AIs的绝经标准. 中华乳腺病杂志. 2012;6(3):238-243.
19. Colleoni M, Sun Z, Price KN, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016 Mar 20;34(9):927-35.
20. Yin W, Di G, Zhou L, et al. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat. 2009 Apr;114(3):527-35.
21. 《乳腺癌内分泌治疗专家共识（2023版）》
22. 范蕾,等. 中国绝经前激素受体阳性乳腺癌辅助内分泌治疗最小成本分析. 中国药物经济学. 2020;15(4):5-10
23. Fabrice Andre, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(35):3959-3977.   
24. 中国抗癌协会乳腺癌专业委员会 中华医学会肿瘤学分会乳腺肿瘤学组, 等. 中国抗癌协会乳腺癌诊治指南与规范(2024年版) 《中国癌症杂志》 2023年33卷12期 1092-1186页
25. Yeo W, et al. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat. 2019;177(3):549-559.
26. 《CSCO乳腺癌诊疗指南2021》.中国临床肿瘤学会指南工作委员会
27. 中国年轻乳腺癌诊疗专家共识（2022版）
28. Xue W, Peng Y, et al. Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study). EClinicalMedicine. 2023 Sep 22:64:102243.
29. Zhenzhen Liu, et al. 2023 SABCS. PO2-16-08